The Administrative Core will oversee and monitor all aspects ofthe Program. Dr. White, as PI, will interact on a weekly (minimally), often daily, basis with the other Project Pls, including Drs. Day and Aganwal. He will meet daily with Ms. Cheatham to discuss all pressing matters regarding the program, including upcoming CounterACT meetings, progress reports, interactive meetings with collaborators, meetings of the Internal (lAC) and External Advisory Committees (EAC), implementation of any new directives/mandates from NIH program staff, development of new scientific initiatives within the program as a result of lAC and or EAC recommendations, preparation of responses to EAC recommendations, monitoring of the program's CounterACT website, monitoring the training and progress of sponsored pre-doctoral, postdoctoral, and junior faculty involved in the program in Denver and at collaborating sites. Likewise, he will make decisions and take actions to respond to any of these matters and any other upcoming deadlines relevant to the program. He will be involved, along with Drs. Day and Aganwal, in recmiting new personnel among academic trainees and technical staff. He will coordinate and facilitate collaborative interactions between the projects in Denver and with the offsite collaborators, and he will initiate new offsite collaborations as required by new scientific directions and recommendations by the EAC and NIH administrative staff. He will write and submit grant supplements and, if available, carry fonward requests in order to allow success towards these mandates. He will oversee the Quality Assurance program throughout the Denver CounterACT group, and, in particular, monitor progress of each Project towards its timely achievement of its milestones and the quality of the data documenting that progress. Finally, he will convene regular meetings ofthe project Pls and their trainees to discuss scientific progress. He will assist all members of the team in their preparation of presentations and posters for the annual CounterACT meeting and all regional and national scientific meetings where CounterACT program findings will be presented. He will also interact regularly with Dr. Robert Mason to discuss potential regular guest speakers in the biodefense area and to prepare an annual symposium day on chemical defense and biodefense for the Denver area. Finally, he will oversee industry interactions of the program, including regular review of agents showing potential for rescue of injury due to mustard and/or chlorine and their product development. He will interact with industry partners to try to assure continued progress toward development of products after they have left the pre-clinical arena of the proof-of-principle studies routinely included in the CounterACT program. These would include presentations to, and applications for, BARDA, DTRA, and other DoD-sponsored grants for GLP studies and eventual FDA approval. All of the above-described activities have been among the daily, or at least regular, activities of the Administrative Core during the last cycle.

National Institute of Health (NIH)
National Institute of Environmental Health Sciences (NIEHS)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-MDCN-J)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Colorado Denver
United States
Zip Code
Houin, Paul R; Veress, Livia A; Rancourt, Raymond C et al. (2015) Intratracheal heparin improves plastic bronchitis due to sulfur mustard analog. Pediatr Pulmonol 50:118-26
Goswami, Dinesh G; Kumar, Dileep; Tewari-Singh, Neera et al. (2015) Topical nitrogen mustard exposure causes systemic toxic effects in mice. Exp Toxicol Pathol 67:161-70
Tewari-Singh, Neera; Jain, Anil K; Orlicky, David J et al. (2014) Cutaneous injury-related structural changes and their progression following topical nitrogen mustard exposure in hairless and haired mice. PLoS One 9:e85402
Rancourt, Raymond C; Ahmad, Aftab; Veress, Livia A et al. (2014) Antifibrinolytic mechanisms in acute airway injury after sulfur mustard analog inhalation. Am J Respir Cell Mol Biol 51:559-67
Inturi, Swetha; Tewari-Singh, Neera; Agarwal, Chapla et al. (2014) Activation of DNA damage repair pathways in response to nitrogen mustard-induced DNA damage and toxicity in skin keratinocytes. Mutat Res 763-764:53-63
Jain, Anil K; Tewari-Singh, Neera; Inturi, Swetha et al. (2014) Histopathological and immunohistochemical evaluation of nitrogen mustard-induced cutaneous effects in SKH-1 hairless and C57BL/6 mice. Exp Toxicol Pathol 66:129-38
Ahmad, Shama; Ahmad, Aftab; Neeves, Keith B et al. (2014) In vitro cell culture model for toxic inhaled chemical testing. J Vis Exp :
Day, Brian J (2014) Antioxidant therapeutics: Pandora's box. Free Radic Biol Med 66:58-64
Tewari-Singh, Neera; Inturi, Swetha; Jain, Anil K et al. (2014) Catalytic antioxidant AEOL 10150 treatment ameliorates sulfur mustard analog 2-chloroethyl ethyl sulfide-associated cutaneous toxic effects. Free Radic Biol Med 72:285-95
Jain, Anil K; Tewari-Singh, Neera; Inturi, Swetha et al. (2014) Myeloperoxidase deficiency attenuates nitrogen mustard-induced skin injuries. Toxicology 320:25-33

Showing the most recent 10 out of 38 publications